Michael S. Kivowitz is a Partner in the Healthcare and Litigation practice groups at Mandelbaum Barrett PC where he represents a wide variety of clients including a wide range of healthcare providers, laboratories and pharmacies in both State and Federal Courts. He started his legal career representing no-fault insurance carriers in civil matters involving healthcare fraud as well as State and Federal RICO (Racketeering Influenced Corrupt Organization) violations against healthcare providers and other healthcare business professionals. Prior to joining the firm, Michael represented physicians, health care professionals, hospitals, nursing facilities and health care systems in malpractice actions, risk management investigations, as well as investigations brought by state regulatory and oversight boards.

Additionally, Michael was previously the Managing Partner of a medical malpractice firm in New York City and has handled a variety of cases including New York Labor Law, Products Liability, Employment Law and Insurance Coverage.  He holds a law degree from the University of Miami School of Law, where he served as the Senior Articles and Comments editor for the Business Law Review, and an undergraduate degree from the University of Michigan.

In his free time, Michael is the treasurer of the Tenafly Little League, and also coaches basketball for Tenafly Youth Basketball.  He is a past treasurer of the J. Spencer Smith Elementary School HSA in Tenafly.

  • New York State
  • Southern District of New York
  • Eastern District of New York
  • New Jersey
  • Florida
  • Middle District of Florida
  • District of New Jersey

  • University of Miami School of Law
  • University of Michigan

Healthcare Alert: Eli Lilly Dismisses Lawsuit Against Mandelbaum Barrett PC’s Pharmacy Client in Florida

April 30, 2024

In the summer and fall of 2023, certain pharmaceutical companies, such as Novo Nordisk (Ozempic, Wegovy, and Rybelsus) and Eli Lilly (Mounjaro), filed lawsuits across the country against medical spas and wellness centers, compounding facilities, and pharmacies that dispense drugs containing the active pharmaceutical ingredient semaglutide (Novo Nordisk) or tirzepatide (Eli Lilly). These drugs have […]